# Ovarian Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/ovarian-cancer

> 8 upcoming FDA catalysts in ovarian Cancer: INCB123667 (INCY) on Apr to Jul 2027 (topline data readout); INCB123667 (INCY) on April 2027 (primary completion); INCB123667 (INCY) on Nov 2028 to Feb 2029 (topline data readout); INCB123667 (INCY) on November 2028 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 1, 2025 | [Pamiparib capsule primary completion](https://sec-api.dev/pdufa/pamiparib) | ONC | Ovarian Cancer | completed | "NCT03519230 (Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03519230)) |
| July 2026 | [LYNPARZA® (olaparib) primary completion](https://sec-api.dev/pdufa/olaparib) | AZN | Ovarian Cancer | delayed | "NCT04884360 (D9319C00001- 1L OC Mono Global RCT): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04884360)) |
| Apr to Jul 2027 | [INCB123667 topline data readout](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07023627 (A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023627)) |
| April 2027 | [INCB123667 primary completion](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07023627 (A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023627)) |
| Nov 2028 to Feb 2029 | [INCB123667 topline data readout](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07214779 (Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07214779)) |
| November 2028 | [INCB123667 primary completion](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07214779 (Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07214779)) |
| January 2029 | [Mirvetuximab soravtansine primary completion](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | Ovarian Cancer | scheduled | "NCT07059845 (A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07059845)) |
| Jan to Apr 2029 | [Mirvetuximab soravtansine topline data readout](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | Ovarian Cancer | scheduled | "NCT07059845 (A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07059845)) |
| March 2030 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Ovarian Cancer | scheduled | "NCT07859215 (Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859215)) |
| Mar to Jun 2030 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Ovarian Cancer | scheduled | "NCT07859215 (Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859215)) |

## Drugs

- [Pamiparib capsule](https://sec-api.dev/pdufa/pamiparib) (ONC)
- [LYNPARZA® (olaparib)](https://sec-api.dev/pdufa/olaparib) (AZN)
- [INCB123667](https://sec-api.dev/pdufa/incb123667) (INCY)
- [Mirvetuximab soravtansine](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) (ABBV)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/ovarian-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ovarian Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/ovarian-cancer

```bibtex
@misc{secapidev_indications_ovarian_cancer_20261116,
  title        = {Ovarian Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/ovarian-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_ovarian_cancer_20261116","title":"Ovarian Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/ovarian-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
